Celldex Drug Flashes Potential to Compete With, Maybe Beat Rival Big Pharma Meds

By On Nov 6, 2023

Celldex drug barzolvolimab has mid-stage results in a chronic inflammatory skin disease that top those of an approved Genentech drug and two experimental Novartis therapies. The biotech is preparing to advance its drug to Phase 3 testing in 2024.

Urban Institute: 400,000 Veterans Expected to be Uninsured in 2024

RCM Staff Shortages Are Making It a Lot Harder for Providers to Get Paid